Antibiotic resistance from two perspectives: Man and microbe

International Journal of Antimicrobial Agents

Volumn 23, Issue 3, 2004, Pages 209-212

  Hamilton Miller, J M T ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Alternatives to antibiotics; Antibiotic resistance; Selection pressure

Indexed keywords

ANTIBIOTIC AGENT; ANTIMALARIAL AGENT; BAMBERMYCIN; BETA LACTAM ANTIBIOTIC; CARBON MONOXIDE; CLAVULANIC ACID; EPICATECHIN GALLATE; ERYTHROMYCIN; HYDROGEN SULFIDE; IMMUNOMODULATING AGENT; MEPACRINE; METHANOL; METICILLIN; PENICILLIN G; PROBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; SULBACTAM; SULFONAMIDE; TAZOBACTAM; TETRACYCLINE;

ALTERNATIVE MEDICINE; ANTIBIOTIC RESISTANCE; BACTERIAL GENETICS; BACTERIAL SURVIVAL; BIOCHEMISTRY; EVOLUTION; HOST PARASITE INTERACTION; HUMAN; IMMUNOTHERAPY; INFECTION; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; REVIEW; STRESS; TEA;

EID: 1442360950     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2003.12.001     Document Type: Note

References (33)

1. Work TS, Work E. The basis of chemotherapy. London: Oliver & Boyd Ltd.; 1948.
2. Richardson L.P., Wiseman S.W.W., Malani P.N.et al. Effectiveness of a vancomycin restriction policy in changing the prescribing habits of house staff. Microb. Drug Res. 6:2000;327-330.
3. Seppala H., Klaukka T., Vuopio-Varkila J.et al. The effects of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. New Eng. J. Med. 337:1997;441-446.
4. Hamilton-Miller J.M.T. 'Think like a bacterium': a helpful concept to prolong the antibiotic era? Clin. Microbiol. Infect. 4:1998;177-178.
5. Hamilton-Miller J.M.T. The emergence of antibiotic resistance: myths and facts in clinical practice. Intens. Care Med. 16:1990;S206-S211.
6. Labro M.-T. Interference of antibacterial agents with phagocyte functions: immunomodulation or 'immuno-fairy tales'? Clin. Microbiol. Rev. 13:2000;615-650.
7. Hamilton-Miller J.M.T. Immunopharmacology of antibiotics: direct and indirect immunomodulation of defence mechanisms. J. Chemother. 13:2001;107-111.
8. Burns E.R. Biological time and in vivo research: a field guide to pitfalls. Anat. Rec. 261:2000;141-152.
9. Bliwise D.L., Kutner N.G., Zhang R., Parker K.P. Survival by time of day of hemodialysis in an elderly cohort. JAMA. 286:2001;2690-2694.
10. Kelly J. Immunotherapy against antibiotic-resistant bacteria: the Russian experience with an antistaphylococcal hyperimmune plasma and immunoglobulin. Microb. Infect. 2:2000;1383-1392.
11. Sulakvelidze A., Alavidze Z., Morris J.G. Bacteriophage therapy. Antimicr. Ag. Chemother. 45:2001;649-659.
12. Ahmad S.I. Treatment of post-burns bacterial infections by bacteriophages, specifically ubiquitous Pseudomonas spp. notoriously resistant to antibiotics. Med. Hypoth. 58:2002;327-331.
13. Engelberg-Kulka H., Sat B., Hazan R. Bacterial programmed cell death and antibiotics. ASM News. 67:2001;617-624.
14. Huovinen P. Bacteriotherapy: the time has come. Brit. Med. J. 323:2001;353-354.
15. Zopf D., Roth S. Oligosaccharide anti-infective agents. Lancet. 347:1996;1017-1021.
16. Svensson A., Larsson A., Emtenas H.et al. Design and evaluation of pilicides: potential novel antibacterial agents directed against uropathogenic Escherichia coli. Chembiochem. 2:2001;915-918.
17. Scott C.J., McDowell A., Martin S.J.et al. Irreversible inhibition of the bacterial cysteine protease-transpeptidase sortase (SrtA) by substrate-derived affinity labels. Biochem. J. 366:2002;953-958.
18. Dong Y.-H., Gusti A.R., Zhang Q.et al. Identification of quorum-quenching N-acyl homoserine lactonases from Bacillus species. Appl. Environ. Microbiol. 68:2002;1754-1759.
19. Nishikawa K., Matsuoka K., Kita E.et al. A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7. Proc. Natl. Acid. Sci. U.S.A. 99:2002;7669-7674.
20. Potera C. Decoy protein blocks superantigen's effects. ASM News. 67:2001;390-391.
21. Kessler R.C., Davis R.B., Foster D.F.et al. Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann. Int. Med. 135:2001;262-268.
22. Vandenbroucke J.P., de Craen A.J.M. Alternative medicine: a 'mirror image' for scientific reasoning in conventional medicine. Ann. Int. Med. 135:2001;507-513.
23. Cooper R.A., Molan P.C., Harding K.G. The sensitivity to honey of Gram-positive cocci of clinical significance isolated from wounds. J. Appl. Microbiol. 93:2002;857-863.
24. Cox S.D., Mann C.M., Markham J.L.et al. The mode of antimicrobial action of the essential oil of Melaleuca alterniflora (tea tree oil). J. Appl. Microbiol. 88:2000;170-175.
25. Sander P., Springer B., Prammananan T.et al. Fitness cost of chromosomal drug resistance-conferring mutations. Antimicr. Ag. Chemother. 46:2002;1204-1211.
26. Yam T.S., Hamilton-Miller J.M.T., Shah S. The effect of a component of tea (Camellia sinensis) on methicillin resistance, PBP2' synthesis, and β-lactamase production in Staphylococcus aureus. J. Antimicr. Chemother. 42:1998;211-216.
27. Renau T.E., Lemoine R.C. Efflux pump inhibitors to address bacterial and fungal resistance. Drugs Future. 26:2001;1171-1178.
28. Pillai S.P., Pillai C.A., Shankel D.M., Mischer L.A. The ability of certain antimutagenic agents to prevent development of antibiotic resistance. Mutat. Res. 496:2001;61-73.
29. Riedl S., Ohlsen K., Werner G.et al. Impact of flavophospholipol and vancomycin on conjugational transfer of vancomycin resistance plasmids. Antimicr. Ag. Chemother. 44:2000;3189-3192.
30. van den Bogaard A.E., Hazen M., Hoyer M.et al. Effects of flavophospholipol on resistance in fecal Escherichia coli and enterococci of fattening pigs. Antimicr. Ag. Chemother. 46:2002;110-118.
31. Zhao W.H., Hu Z.Q., Hara Y., Shimamura T. Inhibition by epigallocatechin gallate of conjugative R plasmid transfer in Escherichia coli. J. Infect. Chemother. 7:2001;195-197.
32. Yoshikawa M., Sevag M.G. Sensitivity of Escherichia coli to Atabrine conferred by R-factor and its potential clinical significance. J. Bact. 93:1967;245-253.
33. Cohen M.L. Epidemiology of drug resistance: implications for a post-antibiotic era. Science. 257:1991;1050-1055.